Report Cover

North America Antiviral Drugs Market Size By Indication, By Drug Class, By Type, By Age Group, Research Report, Country Outlook, Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 - 2027


Unprecedented rise in COVID-19 cases in the U.S. and Canada has triggered the development of anti-viral therapies, stimulating North America antiviral drugs market value. With the COVID-19 infection tally exceeding 30 million and 900,000 in the U.S. and Canada, respectively, both governments and NGOs had upped investments for the discovery of the COVID-19 anti-viral candidate. 
Increasing cases of viral infections diseases, such as HIV and hepatitis will bode well for the industry outlook. According to the U.S. Department of Health & Human Services, around 2.4 million people were infected with hepatitis C in the U.S. Accordingly, robust demand for active anti-viral drug therapies will propel the industry size expansion. In terms of revenue, North America antiviral drugs market is forecast to surpass USD 24 billion by 2027. 
Protease inhibitors are likely to be sought-after to dent the activity of protease enzymes in the growth of human immunodeficiency virus. The innate ability of protease inhibitors to negate virus replication will bolster the product adoption. The market revenue from the protease inhibitors segment was pegged at more than USD 4 billion in 2020 and will grow at a considerable rate in the next few years.
Considering the upsurge in HIV population in the U.S., growth of antiviral drugs for HIV AIDS indication will gain prominence across the region. According to a study, around 1.2 million people were infected with HIV in the U.S., with approximately 37,968 people accessing diagnosis and testing services in 2018. The HIV AIDS segment logged more than 48% market share in 2020 and is poised to surge by 2027. 
The trend for generic antiviral drugs will be pronounced with the availability of a slew of generic drugs. Considering the cost-efficiency attribute of the antiviral drugs boosting therapeutics' accessibility, end-users will continue to exhibit traction for the product. The industry size from the generic antiviral drugs segment exceeded USD 6.5 billion in 2020.
With increased risk of sexually transmitted diseases among adults, healthcare outlay will be noticeable emphasizing the adult age-group. North America antiviral drugs market revenue from the adult segment logged more than USD 8 billion in 2020 and will gain a substantial ground by 2027.
Canada is likely to be one of the most lucrative markets for the manufacturing of anti-viral drugs. A dramatic rise in product rollouts and R&D activities will augment the product demand. Canada antiviral drugs market revenue registered more than USD 1.5 billion in 2020.
Industry participants will potentially focus on expanding the foothold in the U.S. as infectious diseases rise unabated. The CDC claims that around 35.5 million people were plagued with influenza, triggering close to half a million hospitalizations and claimed more than 30,000 lives during the 2018-2019 influenza season. The U.S. antiviral drugs market size is expected to surpass USD 21.5 billion by 2027. 
Prominent companies are emphasizing partnerships, collaboration and product launches to gain a hold in the region. For instance, Cyclica collaborated with China's Institute of Materia Medica in March 2020 to discover antiviral drug candidates for COVID-19. 
Key developers in North America antiviral drugs market are Bristol-Myers Squibb, Gilead Sciences, Abbvie Inc., and Merck & Co., among others.
Report Content

Chapter 1   Methodology

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.3    References & sources

1.3.1    Secondary

1.3.2    Primary

Chapter 2   Executive Summary

2.1    North America anti-viral drugs industry summary, 2016 - 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age-group trends

Chapter 3   Industry Insights

3.1    Industry segmentation

3.2    Industry outlook, 2016 - 2027

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Increasing prevalence of viral infections including COVID-19

3.3.1.2    Presence of pipeline products for HIV treatment

3.3.1.3    Increasing geriatric population

3.3.1.4    Presence of leading market players in the U

3.3.2    Industry pitfalls & challenges

3.3.2.1    Presence of generics

3.3.2.2    Rising awareness about preventive drugs treatment

3.3.2.3    Drug resistance

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter's analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   North America Anti-viral Drugs Market, By Drug Class

4.1    Market trends

4.2    DNA polymerase inhibitors

4.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3    Reverse transcriptase inhibitors

4.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4    Protease inhibitors

4.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.5    Neuraminidase inhibitors

4.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.6    Others

4.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5   North America Anti-viral Drugs Market, By Indication

5.1    Market trends

5.2    Influenza

5.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3    HIV/AIDS

5.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.5    Herpes Simplex Virus

5.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.6    Coronavirus Infection

5.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.7    Others

5.7.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 6   North America Anti-viral Drugs Market, By type

6.1    Market trends

6.2    Branded

6.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3    Generic

6.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7   North America Anti-viral Drugs Market, By Age Group

7.1    Market trends

7.2    Adult

7.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4    Geriatric

7.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8   North America Anti-viral Drugs Market, By Country

8.1    Market trends

8.2    U.S.

8.2.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.2.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.2.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.2.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.3    Canada

8.3.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.3.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.3.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.3.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Gilead Sciences, Inc

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Product landscape

9.1.4    Strategic outlook

9.2    Johnson & Johnson

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.3    GlaxoSmithKline

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.4    AbbVie Inc.

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.5    Merck & Co.

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.6    Bristol Myers Squibb

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.7    Aurobindo Pharma Ltd.

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.8    Cipla Inc.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.9    Sun Pharmaceutical Industries Ltd

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.10    Viatris Inc.

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:
Publisher: Graphical Research
Chat with us